Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China

doi:10.3748/wjg.v28.i27.3503

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4098)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

190

WORD

HTML

1621

Figures (1-3)

287

Tables (1-3)

337

Sum=2520

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

325

Download

1253

Sum=1578

Jul 21, 2022 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jul 21, 2022; 28(27): 3503-3513
Published online Jul 21, 2022. doi: 10.3748/wjg.v28.i27.3503

Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China

Min-Jun Liao, Jun Li, Wei Dang, Dong-Bo Chen, Wan-Ying Qin, Pu Chen, Bi-Geng Zhao, Li-Ying Ren, Ting-Feng Xu, Hong-Song Chen, Wei-Jia Liao

Min-Jun Liao, Jun Li, Wei Dang, Wan-Ying Qin, Bi-Geng Zhao, Li-Ying Ren, Ting-Feng Xu, Wei-Jia Liao, Laboratory of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical University, Guilin 541001, Guangxi Zhuang Autonomous Region, China

Min-Jun Liao, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China

Jun Li, Genetics and Precision Medicine Laboratory, The Affiliated Hospital of Guilin Medical University, Guilin 541001, Guangxi Zhuang Autonomous Region, China

Dong-Bo Chen, Pu Chen, Hong-Song Chen, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Peking University People’s Hospital, Beijing 100044, China

Author contributions: Liao MJ, Li J, and Dang W contributed equally to this work; Liao WJ was the guarantor and designed the study; Liao MJ, Li J, Chen DB, Qin WY, Chen P, Zhao BG, Ren LY, Xu TF, and Liao WJ participated in the acquisition, analysis, and interpretation of the data; Li J and Dang W drafted the initial manuscript; Chen HS and Liao WJ revised the article critically for important intellectual content.

Supported by the National Natural Science Foundation of China, No. 81372163; the Natural Science Foundation of Guangxi, No. 2018GXNSFDA138001; the Science and Technology Planning Project of Guilin, No. 20190218-1; the Opening Project of Key laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, No. GKE-KF202101; and the Program of Guangxi Zhuang Autonomous Region Health and Family Planning Commission, No. Z20210706 and No. Z20190665.

Institutional review board statement: The study was reviewed and approved by the research ethics committee of Affiliated Hospital of Guilin Medical University.

Informed consent statement: Informed consent was obtained from all patients.

Conflict-of-interest statement: There are no conflicts of interest to report.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Wei-Jia Liao, MD, Chief Doctor, Professor, Laboratory of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical University, No. 15 Lequn Road, Xiufeng District, Guilin 541001, Guangxi Zhuang Autonomous Region, China. liaoweijia288@163.com

Received: February 14, 2022
Peer-review started: February 14, 2022
First decision: March 9, 2022
Revised: March 23, 2022
Accepted: June 18, 2022
Article in press: June 18, 2022
Published online: July 21, 2022

Core Tip

Core Tip: Chronic hepatitis B virus (HBV) infection is highly endemic in China, and routine assessment of chronic hepatitis B patients is greatly needed to guide management and indicate the need for treatment. In this study, we established a new index to stage liver fibrosis and cirrhosis in patients with chronic HBV infection in China. In addition, the study compared the predictive performance between the new index and other noninvasive indices. The new index is suitable for regular monitoring and is crucial for the management of patients with liver fibrosis/cirrhosis.